Skip to content
Menu

Bausch + Lomb Corporation BLCO

Full chart Compare
Set alert

Price alert · BLCO

All alert types
19.38 USD -1.31 (-6.33%)

Regular-session close

19.40 +0.02 +0.10%

After hours · Nov 20, 7:23 PM ET

19.30 Day range 20.50
14.56 52-week range 21.37
YTD
+13.47%
1 year
+33.10%

5D -1.86 (-8.76%)

2021MonTueWedThuFri19.38
Market cap
6.93B
Revenue (ttm)
5.42B
Profit margin
-2.05%
EPS (ttm)
-0.32
Shares out
357.50M
Forward P/E
16.37
YTD return
+13.47%
1-year return
+33.10%
50-day average
18.23
200-day average
16.94
Volume
872.06K
Avg volume
650.80K
Open
20.24
Previous close
20.69
Day's range
19.30 – 20.50
52-week range
14.56 – 21.37
Beta
0.52
Analysts
Buy
Price target
21.93 (+13.2%)
Earnings date
Feb 17, 2027

Key statistics

Enterprise value
12.05B
PEG ratio
0.89
Price / sales
1.28
Price / book
1.08
Revenue growth
7.30%
Free cash flow
404.38M
Total cash
513.00M
Total debt
5.10B
Return on equity
-1.58%
Short % of float
5.64%

Fundamental scorecard

6 of 25 checks passed on BLCO’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 1 of 5
  • Growth 3 of 5
  • Profitability 1 of 5
  • Financial health 1 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
BLCO Revenue — quarterly 1.38B
BLCO Net income — quarterly 32.00M
BLCO EPS — quarterly 0.09

Earnings

BLCO recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 17, 2027Dec 30, 20260.36———
Oct 28, 2026Sep 30, 20260.21450.34+0.13+58.51%
Jul 29, 2026Jun 30, 20260.15440.16+0.01+3.63%
Apr 29, 2026Mar 31, 20260.060.08+0.02+33.33%
Feb 18, 2026Dec 31, 20250.350.32-0.03-8.57%
Oct 29, 2025Sep 30, 20250.160.18+0.02+12.50%

Upgrades / downgrades

BLCO analyst upgrades and downgrades
DateFirmActionFromTo
Nov 2, 2026HC Wainwright & Co.downBuyNeutral
Oct 29, 2026JP MorganmainNeutralNeutral
Oct 29, 2026CitigroupmainBuyBuy
Oct 29, 2026RBC CapitalmainOutperformOutperform
Oct 29, 2026Wells FargomainEqual-WeightEqual-Weight
Oct 7, 2026Barclaysinit—Overweight

About Bausch + Lomb Corporation

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.

Sector
Healthcare
Industry
Medical Instruments & Supplies
Country
Canada
Website
bausch.com

News

Your note

Sign in to keep a note on BLCO — it syncs with the Stock Master app.

Insider holders

BLCO insider holders
InsiderRelationLatest transactionDateShares held
BAILEY AMBROSE ROBERT DOUGLAS J.D.OfficerStock Award(Grant)Aug 4, 2026264,241
BERNIER NATHALIE DDirectorStock Award(Grant)May 25, 202685,505
BONNEFOY LUCOfficerStock Award(Grant)Aug 4, 2026103,801
ELDESSOUKY OSAMA AChief Financial OfficerStock Award(Grant)Aug 4, 2026393,527
ELDESSOUKY SAMChief Financial OfficerPurchaseMar 5, 2026407,130
HASHAD YEHIAOfficerStock Award(Grant)Aug 4, 2026187,350

Institution ownership

BLCO institution ownership
Holder% heldSharesValueReported
Brookfield Corp /ON/1.28%4,565,71988.51MSep 29, 2026
Shaw D.E. & Co., Inc.0.94%3,379,70465.52MSep 29, 2026
Deutsche Bank AG0.93%3,329,25764.54MSep 29, 2026
Davidson Kempner Capital Management LP0.88%3,158,97261.24MSep 29, 2026
Goldentree Asset Management LP0.87%3,106,98760.23MSep 29, 2026
Icahn Carl C0.66%2,378,10046.10MSep 29, 2026

Fund ownership

BLCO fund ownership
Holder% heldSharesValueReported
T. Rowe Price High Yield Fund, Inc.0.23%837,05016.23MAug 30, 2026
TR PRICE-Price (T.Rowe) U.S. High Yield Trust0.13%454,2208.81MJun 29, 2026
T. ROWE PRICE Intl Fd.S, INC.-T. Rowe Price Dynamic Credit Fd.0.06%204,4913.96MJun 29, 2026
T. ROWE PRICE Inst. INCOME Fd.S, INC.-T. Rowe Price Inst. High Yield F0.06%218,2114.23MAug 30, 2026
Unified Series Trust-BALLAST SMALL/MID CAP ETF0.04%147,8372.87MJun 29, 2026
Gabelli Healthcare & WellnessRx Trust0.04%144,0002.79MSep 29, 2026